Effective immunotherapies for AD, PD, and ALS (including monoclonal antibodies and therapeutic vaccines for prion-like proteins such as beta-amyloid, tau, alpha-synuclein and TDP-43) are on the horizon. This evidence concerns the gene MAPT and Alzheimer disease.